Bupa launches an initiative in personalized healthcare to offer whole genome sequencing to select customers in the UK. The whole genome sequencing program aims to transform the way health risks are identified and managed, making it a significant innovation in the healthcare landscape.

My Genomic Health Pilot

Bupa has launched a two-year pilot program called “My Genomic Health,” establishing itself as the first major private healthcare provider in the UK to offer whole genome sequencing to selected customers. Approximately 3,700 customers will benefit from the program.

Scope of Genetic Testing

This program analyzes over 300 genes and nine polygenic risk scores to assess genetic risks for more than 36 different diseases. Among these are significant conditions such as heart disease, metabolic diseases, and ten types of cancer, including breast, prostate, skin, and bowel cancer.

Personalized Health Plans

Customers identified with high genetic risk through whole genome sequencing will receive personalized recommendations. This includes tailored health plans to prevent illness or facilitate early detection and treatment. This includes access to genetic counseling and onward referrals to Bupa services like GP or specialist consultations if necessary.

Additional Genetic Insights

The testing will offer insights into carrier gene status and pharmacogenomics. It’s expected to enhance the understanding of how individuals respond to medications based on their genetic profiles.

Preventative Focus

Bupa designs its initiative to shift healthcare’s focus from merely treating illnesses to effectively preventing them. It empowers customers to take proactive steps in their daily lives to mitigate health risks.

Future Expansion

After the pilot, Bupa intends to offer whole genome sequencing as an optional add-on to Bupa Health Assessments for women aged over 40 and men over 45 starting in early 2025. A Health Insights Polygenic Risk Scoring (PRS) test will also be launched to evaluate risks for conditions such as breast cancer, prostate cancer, Type 2 diabetes, and cardiovascular disease.

Post-Diagnosis Genetic Testing

Bupa provides genetic tests for customers already diagnosed with certain conditions. These tests include Signatera for colorectal or bladder cancer and CIRT for treatment with Immune Checkpoint Inhibitors, among others.

Clinical and Operational Leadership

The program is directed by Dr. Rishi Patel, Head of Clinical Transformation at Bupa, and Sarah Melia, General Manager for Bupa Health Services. They are instrumental in the development and execution of this innovative genomics program.

Overall, Bupa’s initiative in whole genome sequencing marks a crucial advancement toward personalized and preventative healthcare. It aims to empower customers in managing their health effectively by providing genetic insights and customized health plans. In doing so, it establishes a new standard in healthcare driven by innovation.